Source-grounded facts extracted from Fortress Biotech, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Fortress Biotech, Inc. reported financial results for the year ended December 31, 2025.
“On March 31, 2026, Fortress Biotech, Inc. issued a press release to provide a corporate update and to announce its financial results for the year ended December 31, 2025.”
Fortress Biotech, Inc. amended Second Amendment to Credit Agreement with Oaktree Fund Administration, LLC valued at Amended credit agreement dated July 25, 2024; $35.0 million initial borrowing, up to $15.0 million a (effective 2026-02-22).
“On February 22, 2026, the Company, as borrower, entered into the Second Amendment to Credit Agreement (the “ Second Amendment ”), which amends that certain Credit Agreement dated July 25, 2024 (the “ Original Agreement ”) with Oaktree Fund Administration, LLC, as the administrative agent (in such capacity, the “ Agent ”), and the lenders from time to time party thereto (as amended by that certain First Amendment to Credit Agreement dated December 12, 2025, collectively with the Original Agreement and the Second Amendment, the “ Loan Agreement ”).”
Fortress Biotech, Inc. entered into Priority Review Voucher Asset Purchase Agreement with Cyprium Therapeutics, Inc. valued at $205 million (effective 2026-02-22).
“On February 22, 2026, Cyprium Therapeutics, Inc. (“Cyprium”), a majority-owned subsidiary of Fortress Biotech, Inc. (the “ Company ”), entered into a definitive asset purchase agreement (the “ PRV APA ”) pursuant to which Cyprium agreed to sell a Rare Pediatric Disease Priority Review Voucher (“ PRV ”).”
Fortress Biotech, Inc. amended credit facility of up to $50.0 million with Oaktree Fund Administration, LLC maturing June 30, 2028.
“Under the terms of the Amendment, the Loan’s maturity date was extended from July 25, 2027 to June 30, 2028.”
Fortress Biotech, Inc. completed a disposition involving Sun Pharmaceutical Industries, Inc. for approximately $28.0 million in cash (closed 2025-05-30).
“as a subsidiary of Fortress (the “Subsidiary Sale”). In connection with the closing of the Merger and pursuant to the Merger Agreement, Fortress will receive approximately $28.0 million in cash and be eligible to receive up to an additional $4.8 million upon achievement of a regulatory milestone associated with the rights (“CVRs”) issued under a Contingent Value”
Lucy Lu was appointed as Chief Strategy Officer at Fortress Biotech, Inc..
“Dr. Lu’s decision to resign from the Board of Directors was made in connection with her accepting an offer to join the Company as Chief Strategy Officer effective April 21, 2025.”
Lucy Lu resigned as Director at Fortress Biotech, Inc..
“On April 15, 2025, Lucy Lu, M.D., notified Fortress Biotech, Inc. (the “ Company ”) of her resignation from the Board of Directors effective April 15, 2025.”
Fortress Biotech, Inc. reported financial results for first quarter ended March 31, 2024.
“Fortress Biotech, Inc. issued a press release to provide a corporate update and to announce its financial results for the three months ended March 31, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.